CYP2C76-mediated species difference in drug metabolism: A comparison of pitavastatin metabolism between monkeys and humans

References

• Aoki T, Yoshinaka Y, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y. Triglyceride-lowering effect of pitavastatin in a rat model of postprandial lipemia. European Journal of Pharmacology 2002; 444: 107–113
   PubMed Web of Science ®Google Scholar
• Bogaards JJP, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, Bladeren PJ, Walther B. Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000; 12: 1131–1152
   Web of Science ®Google Scholar
• Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, Nishioka Y, Kamataki T. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12: 299–306
   PubMedGoogle Scholar
• Fujino H, Kojima J, Yamada Y, Kanda H, Kimata H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans. Xenobiotic Metabolism and Disposition 1999a; 14: 79–91
   Google Scholar
• Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid form and lactone form of HMG-CoA reductase inhibitors. Xenobiotica 2004b; 34: 961–971
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Tsunenari Y, Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin – Determining the best animal model for human CYP and UGT activities. Drug metabolism and Drug Interactions 2004a; 20: 25–42
   PubMedGoogle Scholar
• Fujino H, Yamada I, Hirano M, Yoneda M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobiotic Metabolism and Disposition 1999b; 14: 415–424
   Google Scholar
• Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003; 33: 27–41
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Shimada S, Yoneda M. Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay. Journal of Chromatography 2001; 757: 143–150
   Web of Science ®Google Scholar
• Hichiya H, Kuramoto S, Yamamoto S, Shinoda S, Hanioka N, Narimatsu S, Asaoka K, Miyata A, Iwata S, Nomoto M, Satoh T, et al. Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: Comparison with the known marmoset CYP2D19. Biochemical Pharmacology 2004; 68: 165–175
   PubMed Web of Science ®Google Scholar
• Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochemical Pharmacology 1998; 55: 1315–1325
   PubMed Web of Science ®Google Scholar
• Jacqz E, Billante C, Moysan F, Mathieu H. The non-human primate: A possible model for human genetically determined polymorphisms in oxidative drug metabolism. Molecular Pharmacology 1988; 34: 215–217
   PubMed Web of Science ®Google Scholar
• Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yonemitsu M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobiotic Metabolism and Disposition 1998; 13: 484–498
   Google Scholar
• Kojima J, Fujino H, Yosimura M, Morikawa H, Kimata H. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography (B) 1999; 724: 173–180
   Web of Science ®Google Scholar
• Komori M, Kikuchi O, Sakuma T, Funaki J, Kitada M, Kamataki T. Molecular cloning of monkey liver cytochrome P-450 cDNAs: Similarity of the primary sequences to human cytochromes P-450. Biochimica et Biophysica Acta 1992; 1171: 141–146
   PubMed Web of Science ®Google Scholar
• Ludwig E, Wolfinger H, Ebner T. Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. Journal of Chromatography 1998; 707: 347–350
   Web of Science ®Google Scholar
• Matsunaga T, Ohmori S, Ishida M, Sakamoto Y, Nakasa H, Kitada M. Molecular cloning of monkey CYP2C43 cDNA and expression in yeast. Drug Metabolism and Pharmacokinetics 2002; 17: 117–124
   PubMedGoogle Scholar
• Mise M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T. Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics 2004; 14: 769–773
   PubMedGoogle Scholar
• Narimatsu S, Kobayashi N, Masubuchi Y, Horie T, Kakegawa T, Kobayashi H, Hardwick JP, Gonzalez FJ, Shimada N, Ohmori S, Kitada M, et al. Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes. Chemico-Biological Interactions 2000; 15: 73–90
   Web of Science ®Google Scholar
• Nedelcheva V, Gut I. P450 in the rat and man: Methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 1994; 24: 1151–1175
   PubMed Web of Science ®Google Scholar
• Norgren Jr RB. Creation of non-human primate neurogenetic disease models by gene targeting and nuclear transfer. Reproductive Biology and Endocrinology 2004; 2: 40
   PubMedGoogle Scholar
• Ohi H, Toratani S, Komori M, Miura T, Kitada M, Kamataki T. Comparative study of cytochrome P-450 in liver microsomes. A form of monkey cytochrome P-450, P-450-MK1, immunochemically cross-reactive with antibodies to rat P-450-male. Biochemical Pharmacology 1989; 38: 361–365
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metabolism and Disposition 1996; 24: 634–642
   PubMed Web of Science ®Google Scholar
• Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA. Comparisons of phase one and phase two in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition 1995; 23: 1231–1241
   PubMed Web of Science ®Google Scholar
• Stevens JC, Shipley LA, Cashman JR, Vandenbranden M, Wrighton SA. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metabolism and Disposition 1993; 21: 753–760
   PubMed Web of Science ®Google Scholar
• Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 1999; 146: 259–270
   PubMed Web of Science ®Google Scholar
• Tenmizu D, Endo Y, Noguchi K, Kamimura H. Identification of the novel canine CYP1A2 1117C > T SNP causing protein deletion. Xenobiotica 2004; 34: 835–846
   PubMed Web of Science ®Google Scholar
• Uno Y, Fujino H, Kito G, Kamataki T, Nagata R. CYP2C76, a novel CYP in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Molecular Pharmacology 70 2006; 477–486
   PubMed Web of Science ®Google Scholar
• Weaver RJ, Dickins M, Burke MD. A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in the cynomolgus monkey (Macaca fascicularis) and man. Xenobiotica 1999; 29: 467–482
   PubMed Web of Science ®Google Scholar
• Weaver RJ, Thompson S, Smith G, Dickins M, Elcombe CR, Mayer RT, Burke MD. A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster liver microsomes. Biochemical Pharmacology 1994; 47: 763–773
   PubMed Web of Science ®Google Scholar
• Yamada I, Fujino H, Shimada S, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica 2003; 33: 789–803
   PubMed Web of Science ®Google Scholar